As Medicare Advantage (MA) open enrollment is currently in full swing, it’s the ideal time to circle back and delve deeper into the substantial changes outlined in the 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F).1 These changes, rooted in a resolute commitment to equity and enhanced healthcare access, are designed to safeguard beneficiaries, bolster quality measures, and promote health equity among all Medicare recipients.
In part one of this two-part blog, we examined the key changes to utilization management, marketing requirements, the Star Rating Program, and CMS’s efforts to advance health equity. In this second part, we’ll continue to explore the key provisions of the final rule and the impact on payers.
The CMS final rule includes several changes to ensure that enrollees have timely access to the behavioral health care they need, including:
These new requirements could be challenging for payers to implement, particularly smaller payers with limited resources. Payers may need to invest in new systems, such as network management, prior authorization, and care coordination systems, to comply with the new requirements. Additionally, they may have to expand their networks to include more behavioral health providers to enhance enrollees’ access to behavioral healthcare.
The Consolidated Appropriations Act (CAA) of 2021 (Division B, Section 118) makes the Limited Income Newly Eligible Transition (LI NET) Program permanent. The LI NET Program provides immediate and retroactive Part D coverage for eligible low-income beneficiaries who do not yet have prescription drug coverage. This change will ensure that low-income individuals can access affordable prescription drug coverage as soon as they become eligible for Medicare Part D.
Beginning January 1, 2024, the Inflation Reduction Act of 2022 (IRA) [Section 13531(a)(1)(A)] expands eligibility for the full low-income subsidy (LIS) benefit (also known as “Extra Help”) to individuals with incomes up to 150% of the federal poverty level. This change will provide the full low-income subsidy to those who currently qualify for the partial subsidy, improving access to affordable prescription drug coverage for approximately 300,000 low-income individuals with Medicare.
These changes will impact payers in several ways. First, the permanent extension of the LI NET Program and the expansion of eligibility for the full LIS benefit will increase enrollees receiving subsidies for their prescription drug coverage. This could lead to increased costs for payers.
The final rule finalizes several changes to the Medicare Part C and D programs stemming from the Bipartisan Budget Act (BBA) of 2018 (Public Law 115-391), the CAA of 2021, and the Inflation Reduction Act (IRA) of 2022 (Section 13531).
Key changes include:
The changes will significantly impact payers, requiring them to adapt their business models and partner with providers to improve the quality and efficiency of care delivery. However, the changes also offer opportunities for payers to serve more enrollees and expand their offerings.
The CMS final rule updates for 2024 will significantly impact payers, but they also present an opportunity to transform healthcare delivery. At HealthAxis, we are committed to helping payers navigate these changes and emerge stronger than ever.
Schedule a discovery call today to learn how HealthAxis can help you transform your health plan operations with our cutting-edge CAPS technology, modern BPaaS/BPO capabilities, and industry expertise.
Source:
1. Fact sheet 2024 Medicare Advantage and Part D Final Rule (CMS-4201-F), CMS